NR3C2 and myocardial infarction: Angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARBs), beta-blockers, and aldosterone receptor antagonists (MRAs) are the mainstays of treatment for patients with LVSD after myocardial infarction (46).